Liver study tests new drug dosing

NCT ID NCT06336018

Completed Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how the body processes a single dose of the drug etavopivat in people with mild, moderate, or severe liver disease compared to those with healthy livers. 48 adults took part. The goal was to understand how liver function affects drug levels and safety, which helps guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: etavopivat
What this could lead to: If successful, this study could help doctors determine the right dose of etavopivat for patients with liver problems.
What could go wrong: This is an early-phase study with only a single dose, so results may not predict long-term safety or effectiveness. Liver impairment can vary widely, making it hard to generalize.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER DISEASES

Contacts and locations

Locations

Amer. Rrsch Corp-TX Liver Inst

San Antonio, Texas, 78215, United States
Cure Clinical Research LLC

Orange, California, 92866, United States
Orlando Clinical Research Center

Orlando, Florida, 32806, United States
Orlando Clinical Research Center

Orlando, Florida, 32809, United States
Pinnacle Clinical Research

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.